Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Pernot

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2022
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancerViolaine Randrian, Simon Pernot, Karine Le Malicot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2024
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instabilityMathilde Moreau, Emily Alouani, Clémence Flecchia, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
The Oncologist|February 12, 2020
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)Lola-Jade Palmieri, Laurent Mineur, David Tougeron, et al.
NPJ Precision Oncology|November 25, 2025
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patientsCristina Smolenschi, Saumya D Sisoudiya, Antoine Hollebecque, et al.
The Oncologist|June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based studyCamille Evrard, Antoine Pelras, Simon Rivet, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2022
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancerViolaine Randrian, Simon Pernot, Karine Le Malicot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2024
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instabilityMathilde Moreau, Emily Alouani, Clémence Flecchia, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
The Oncologist|February 12, 2020
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)Lola-Jade Palmieri, Laurent Mineur, David Tougeron, et al.
NPJ Precision Oncology|November 25, 2025
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patientsCristina Smolenschi, Saumya D Sisoudiya, Antoine Hollebecque, et al.
The Oncologist|June 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based studyCamille Evrard, Antoine Pelras, Simon Rivet, et al.
Pageof 11